OBJECTIVES The aim of this study was to analyze the pacemaker implantation rate (PMIR) with the new balloon-expandable Edwards SAPIEN 3 valve (S3) and the factors associated with it.
T ranscatheter aortic valve replacement (TAVR) has become an accepted treatment alternative for severe aortic stenosis in patients at high surgical risk (1, 2) . Atrioventricular conduction abnormalities (AVCAs) are a common complication after TAVR (3) (4) (5) (6) (7) and are associated with an increased permanent pacemaker (PPM) implantation rate (PPMIR) (8) (9) (10) . This remains one of the concerns with this intervention, particularly when considering even lower risk patients for TAVR. In general, the reported occurrence of AVCAs and need for PPM implantation was markedly lower for balloon-expandable valves than for selfexpandable valves (10) (11) (12) . Studies with the balloon-expandable Edwards SAPIEN XT valve (XT) (Edwards Lifesciences, Irvine, California) have reported an average PPMIR of w6% (range, from 4% to 13%) (13) . The recent introduction of the next generation of balloon-expandable valve of the Edwards SA-PIEN family, the Edwards SAPIEN 3 valve (S3) (Edwards Lifesciences) was suggested to lead to a marked reduction in paravalvular regurgitation (PVR) (14) . This valve incorporates a new adaptive external tissue seal aimed at reducing PVR and its newly designed stent allowing for a lower delivery profile is 3 to 4 mm longer than in the XT. The PPMIR after TAVR with the S3 reported in the release study of the valve was 13.3% (14) , a rate higher than usually reported with the previous generations of the balloon-expandable valve (15) . The markedly higher PPMIR reported for the self-expanding CoreValve (Medtronic, Minneapolis, Minnesota) (range, 24% to 33%) (10) was suggested to be caused by the designrelated extension of the stent deeper into the left ventricular outflow tract (LVOT) (8) . Higher implantation of the valve was indeed reported to reduce the PPMIR (16) . The longer stent of the S3 that may extend deeper into the LVOT may also result in a higher rate of AVCAs compared with the previous valve generation.
It remains, however, currently unclear whether the PPMIR indeed differs between S3 and XT TAVR and which mechanisms may explain such differences.
The aim of the present study was, therefore, to compare the PPMIR between patients undergoing TAVR using S3 and XT valves and to identify risk factors for the development of AVCAs and need for a PPM after S3 implantation, considering in particular the role of the implantation height of the valve. 
RESULTS
During the defined study period, 206 patients underwent TAVR with the S3 (recent cohort) and 371 The flowchart provides information about the included and excluded patients in the SAPIEN 3 and SAPIEN XT groups. ICD ¼ implantable cardioverter-defibrillator; PM ¼ pacemaker; TAVR ¼ transcatheter aortic valve replacement.
De Torres-Alba et al. Table 1 . There were no significant differences in age, sex, baseline risk profile or pre-existing conduction abnormalities between the 2 groups. In the XT group, the most frequently implanted valve size was 26 mm (51.2% vs. 37.7% in the S3 group), whereas in the S3 group, 23-mm was the most frequently used valve size (45.1% vs. 36.2% in the XT group). This difference in implanted valve sizes was statistically significant (p ¼ 0.02). Table 2 shows the post-procedural outcome. The in-hospital mortality (all-cause mortality during index procedure hospitalization) was 2.2% for the entire cohort and did not significantly differ between groups. The mean length of stay was 8 days.
A significant reduction in PVR was observed in the S3 group compared with the XT group (Table 2, The characteristics of S3 patients with and without a need for PPM implantation are presented in Table 3 .
Patients who received a PPM after TAVR did not significantly differ from those without a need for a PPM with regard to age (83. Values are mean AE SD or n (%).
AV ¼ atrioventricular; AVCA ¼ atrioventricular conduction abnormality. Values are n (%).
PPM ¼ permanent pacemaker; PVR ¼ paravalvular regurgitation; other abbreviations as in Table 1 .
De Torres-Alba et al. In order to analyze the influence of this observed temporal trend of a progressively higher implantation of the valve on the PPMIR in the S3 group, we compared the first 50% of patients with the second 50%. The significant increase in the implantation height from 68%/32% to 75%/25% aortic/ventricular PVR has repeatedly been reported to be associated with a worse outcome after TAVR with regard to heart failure rate as well as survival (19) Values are mean AE SD or n (%).
TAVR ¼ transcatheter aortic valve replacement; other abbreviations as in Tables 1 and 2 . The error bars indicate the SD.
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To the best of our knowledge, our study is the 13.0%). In our study, the higher rate of AVCAs of any type observed in the S3 group (39.5% vs. 28.9%
in the XT group) was primarily driven by the higher incidence of third-degree AV block. New-onset left bundle branch block was observed in 13% of patients in the S3 group, a lower rate than the 18% reported in the release study (14) , and it was not associated with a higher PPMIR in the S3 group. The columns show the permanent pacemaker implantation (PPMI) rate in the SAPIEN 3 groups after dividing the cohort into the first 50% of patients and the second 50% of patients treated with SAPIEN 3. The mean implantation height of the valve (% aortic) AE SD in each group is shown.
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